About Kang Stem Biotech
Kang Stem Biotech is a publicly listed company based in Seoul (South Korea) founded in 2010. Stem cell therapies for inflammatory and autoimmune diseases are developed. The company has 95 employees. Its focus areas include Life Sciences, Cell Therapy, Stem Cells and Progenitor Cells.
Company details
Kang Stem Biotech is focussed on developing stem cell-based therapies primarily for inflammatory and autoimmune diseases. It has developed the isolation technology of cord blood-derived stem cells, the mass culturing technology of cord blood-derived stem cells and an easier and efficient technique for inducing human neural stem cells ready for the personalized medicine. Its pipeline has Furestem-AD for Atopic dermatitis (phase 12a completed); Furestem-RA for Rheumatoid Arthritis (phase 1completed) and Furestem-CD (ongoing phase 12a). It also has preclinical candidates for Osteoarthritis, Atherosclerosis and Obliterans.
- Headquarters Seoul, South Korea
- Employees 95
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website kangstem.com
- Social LinkedIn X Facebook
- Legal Name Kangstem Biotech Co., Ltd.
- Annual Revenue$2.47 M (USD)-53.88as on Dec 31, 2025
- Net Profit-$7.26 M (USD)-36.67as on Dec 31, 2025
- EBITDA-$11.37 M (USD)-28.66as on Dec 31, 2025
- Investors
- Employee Count95
Funding Insights of Kang Stem Biotech
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Kang Stem Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2015 | Post-IPO | – | – |
1 investors in total: 1 institutional.
Investors in Kang Stem Biotech
Kang Stem Biotech has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include LB Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth-stage private equity investments are targeted across multiple sectors. | 1996 | lbinvestment.com | Seoul, South Korea |
Investor details for Kang Stem Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Kang Stem Biotech
Kang Stem Biotech is a publicly listed company on the KRX with ticker symbol 217730 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Dec 2015
- Listed onKRX: 217730
- Listed entityKANGSTEM BIOTECH Co., Ltd.
- Exchange sectorHealth technology
- ISINKR7217730001
- Share price1,917.00 KRW (-0.93% on the day) · 2026-10-14
- Market capitalisation181,994,772,148.00 KRW
- EPS (diluted, trailing year)-138.13 KRW
- Volume (last session)184,637
Financials of Kang Stem Biotech
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 3.57B KRW | -10.48B KRW | -16.42B KRW |
| 2024 | 7.75B KRW | -7.67B KRW | -12.77B KRW |
| 2023 | 5.91B KRW | -21.95B KRW | -17.35B KRW |
| 2022 | 16.30B KRW | -20.24B KRW | -17.69B KRW |
| 2021 | 12.40B KRW | -21.35B KRW | -20.90B KRW |
Detailed financial statements for Kang Stem Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Kang Stem Biotech
3 dated milestones of Kang Stem Biotech across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Kang Stem Biotech is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
Web traffic of Kang Stem Biotech
The website of Kang Stem Biotech (kangstem.com) receives about 3K visits a month.
- Monthly visits3K
▼ 13.9% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kang Stem Biotech
Complete news archive for Kang Stem Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kang Stem Biotech
Kang Stem Biotech was founded in 2010 and raised its 1st funding round 5 years after it was founded.
Kang Stem Biotech is headquartered in Seoul, South Korea.
Kang Stem Biotech has 95 employees.
Annual revenue of Kang Stem Biotech is $2.47M as on Dec 31, 2025.
Kang Stem Biotech is focussed on developing stem cell-based therapies primarily for inflammatory and autoimmune diseases. It has developed the isolation technology of cord blood-derived stem cells, the mass culturing technology of cord blood-derived stem cells and an easier and efficient technique for inducing human neural stem cells ready for the personalized medicine. Its pipeline has Furestem-AD for Atopic dermatitis (phase 12a completed); Furestem-RA for Rheumatoid Arthritis (phase 1completed) and Furestem-CD (ongoing phase 12a). It also has preclinical candidates for Osteoarthritis, Atherosclerosis and Obliterans.
Yes, Kang Stem Biotech is publicly traded on KRX under the ticker symbol 217730.
Kang Stem Biotech has 1 investor. Key investors include LB Investment.